IKT Profile
Inhibikase Therapeutics, Inc., a clinical-stage biopharmaceutical firm, is dedicated to advancing novel therapies for Parkinson's disease and related neurodegenerative disorders. The company's flagship product candidate, IkT-148009, is an innovative small molecule designed to inhibit Abelson tyrosine kinase, which is implicated in the pathogenesis of Parkinson's disease and gastrointestinal disorders. This therapeutic approach targets disease mechanisms at the cellular level, offering potential new avenues for managing these debilitating conditions.
Inhibikase Therapeutics is also developing IkT-001Pro, a prodrug formulation of the well-established anticancer agent imatinib mesylate. This compound is being investigated for its potential to treat stable phase chronic myelogenous leukemia (CML), a type of cancer characterized by the overproduction of myeloid cells. The prodrug design aims to enhance the efficacy and safety profile of imatinib, providing a new treatment option for patients with CML.
The company's research and development efforts are bolstered by collaborative partnerships with prestigious institutions, including Johns Hopkins University, Arizona State University, Michigan State University, and Louisiana State University. Additionally, Inhibikase Therapeutics has a collaborative research and development agreement with Sphaera Pharma Pte. Ltd., which supports its ongoing efforts to innovate and advance its therapeutic pipeline.
Established in 2008 and headquartered in Atlanta, Georgia, Inhibikase Therapeutics remains at the forefront of developing targeted treatments for Parkinson's disease and cancer. The company's commitment to leveraging cutting-edge science and strategic partnerships underscores its mission to bring transformative therapies to market and improve patient outcomes in these challenging therapeutic areas.
|
